IGC Pharma, Inc.
For the period ended Oct 10, 2025. Filed Aug 18, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Oct 10, 2025 · Filed Aug 18, 2025
Use the contents to explore the available documents and sections.
IGC$0.20+5.8%Stored close · as of Nov 6, 2026
Contents
Positive Interim Data Reinforces IGC-AD1’s Potential:
| ● | April 2, 2024: IGC Pharma released positive interim data from its ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2, officially named “CALMA” (Calming Agitation in Alzheimer’s) trial for agitation in Alzheimer’s disease, providing early validation of IGC-AD1’s therapeutic promise. The interim data demonstrated a clinical and statistically significant reduction in agitation in patients with Alzheimer’s compared to placebo at week 6, with clinical improvements observed as early as week 2. Agitation affects approximately 76% of the estimated 50 million individuals living with Alzheimer’s worldwide, yet only one treatment is currently FDA-approved—highlighting a vast unmet medical need and multi-billion-dollar opportunity. |
| ● | November 14, 2024: Further interim data from the CALMA trial highlighted additional cognitive benefits of IGC-AD1 in Alzheimer’s patients, Notably, results showed a reduction in sleep disturbances by approximately 71% at week 2 and 78% at week 6 for those on active medication, suggesting a broader impact beyond agitation. These results underscore the potential of IGC-AD1 as a multifaceted treatment for Alzheimer’s symptoms. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.